StockUS listing USCGTXNASDAQHealthcareCapital Destroyer

Cognition Therapeutics Inc(CGTX) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk68Medium-High
50%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 55.37M
Reward Ratingⓘ34 Low reward assessment · 50% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ68 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CGTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Cognition Therapeutics Inc?

, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

AI Brief Pro

The brief on Cognition Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Cognition Therapeutics Inc?

, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 55.37M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.799
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
329,175 shares
$32k
9-12months
0
0